Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial
- 174 Downloads
The aim of this study was to report long-term results of patients with locally advanced rectal cancer treated by neoadjuvant chemoradiotherapy with fluorouracil, leucovorin, and oxaliplatin. From February 2002 to November 2006, a total of 58 patients with locally advanced rectal cancer were recruited. Secondary endpoints included the cumulative incidence of local and distant recurrences, disease-free survival, and overall survival. The median follow-up time was 138 months (109–151 months). The cumulative incidence of local recurrence at 10 years was 12.1 %. The cumulative incidence of distant recurrence at 10 years was 53.4 %. The overall survival in the intention-to-treat population was 39.5 % at 10 years. Disease-free survival in the intention-to-treat population was 41.8 % at 10 years. Univariate analysis revealed that pathologic complete response was associated with local recurrence, distant recurrence, disease-free survival, and overall survival (p < .05). Distant recurrence remains the predominant pattern of failure for patients with locally advanced rectal cancer after preoperative chemoradiotherapy and total mesorectal excision. Pathologic complete response is an independent prognostic factor for locally advanced rectal cancer after preoperative chemoradiotherapy.
KeywordsPreoperative chemoradiotherapy Rectal cancer Oxaliplatin Pathologic complete response
The present study was supported by Zhejiang Province Medical and Health Science and Technology Project (2005B011).
Conflict of interest
All authors declared no conflicts of interest.
- 7.Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245–53.CrossRefPubMedGoogle Scholar
- 8.Liu LY, Zhu Y, Wu L, et al. A phase study of preoperative concurrent chemoradiotherapy of oxaliplatin containing regimen for locally advanced rectal cancer. Chin J Radiat Oncol. 2007;16:286–9.Google Scholar
- 11.Allegra JC, Yothers G, O’Connell MJ, et al. Neoadjuvant therapy for rectal cancer: mature results from NSABP protocol R-04. Gastrointestinal Cancers Symposium. J Clin Oncol. 2014; 32:abstract390.Google Scholar
- 13.Rodel C, Liersch T, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: results of the German CAO/ARO/AIO-04 randomized phase III trial. ASCO Annual Meeting. J Clin Oncol. 2014;32:abstract3500.Google Scholar
- 14.Schmoll H, Haustermans K, Price TJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival results at interim analysis. ASCO Annual Meeting. J Clin Oncol. 2014;32:abstract3501.Google Scholar
- 22.Garcia-Aguilar J, Marcet J, Coutsoftides T, et al. Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer treated with TME. J Clin Oncol. 2011;29:abstr 3514.Google Scholar
- 23.Valentini V, De Paoli A, Gambacorta MA, et al. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092). Int J Radiat Oncol Biol Phys. 2008;72:644–9.CrossRefPubMedGoogle Scholar